Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jbspin.2023.105533 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunological biomarkers in patients with radiographic axial spondyloarthritis, an exploratory longitudinal Swedish study.
Mod Rheumatol
December 2024
Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden.
Objectives: There is a need for more specific biomarkers to diagnose and predict disease course in patients with axial spondyloarthritis (axSpA). This study aimed to study immunological plasma biomarkers at different time-points in radiographic (r)-axSpA patients overall and stratified by sex and compare these biomarker patterns in r-axSpA patients concerning disease phenotypes and disease activity.
Methods: Plasma samples were analysed from r-axSpA patients at and prior (Pre-Backbone) inclusion in the Backbone study.
Year in Review in Axial Spondyloarthritis Clinical Research and Guidelines: SPARTAN 2023 Annual Meeting Proceedings.
Curr Rheumatol Rep
May 2024
Boston University Chobanian & Avedisian School of Medicine, 650 Albany St, Suite 200, Boston, MA, 02118, USA.
Purpose Of Review: To highlight high impact clinical publications in spondyloarthritis from May 2022 to April 2023 that were summarized and presented at the SPARTAN annual meeting in May 2023.
Recent Findings: Publications included updated guidelines on management of axial spondyloarthritis (axSpA) by ASAS-EULAR and development of a modified Juvenile Spondyloarthritis Disease Activity Index (JSpADA). Definitions were published for MRI lesions of the spine in axSpA and active and structural sacroiliac (SI) joint lesions in juvenile spondyloarthritis (JSpA).
CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group.
Haematologica
October 2024
Hematologics Inc., Seattle, WA.
As curative therapies for pediatric acute myleoid leukemia (AML) remain elusive, identifying potential new treatment targets is vital. We assessed the cell surface expression of CD74, also known as the major histocompatibility complex-II invariant chain, by multidimensional flow cytometry in 973 patients enrolled in the Children's Oncology Group AAML1031 clinical trial (clinicaltrials gov. Identifier: NCT01371981).
View Article and Find Full Text PDFDiagnostic value of the anti-CD74 antibodies for axial spondyloarthritis: Results of a prospective study in patients with suspicious low back pain.
Joint Bone Spine
May 2023
Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany.
Macrophage migration inhibitory factor (MIF) and IgA anti CD74 antibodies in Indian patients with enthesitis-related arthritis category of Juvenile idiopathic arthritis.
Rheumatol Int
January 2023
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine and has been implicated in pathogenesis of ankylosing spondylitis (AS). CD 74 is the receptor for MIF and IgA antiCD74 autoantibodies have been described from different parts of the world in patients with AS. As enthesitis-related arthritis (ERA) is a form of juvenile spondyloarthropathy, we studied the serum and synovial fluid levels of MIF in ERA and looked for the IgA antiCD74 antibodies in patients with ERA in our population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!